MYCN and neuroblastoma: To this end, we observed that, in SK-N-BE-2-C (BE2C) and IMR32 neuroblastoma cell lines, treatment with the 26 S proteasome inhibitor MG132 led to a marked increase in endogenous MYCN protein abundance (Fig. 1A, B).